Both in the developing and developed world, it is a grim fact that millions of people suffer from treatable illnesses and disease simply because they cannot afford the medicines that will restore them to health. Even in high income countries like the US, brand name drugs are often prohibitively expensive, particularly for the growing numbers of uninsured. Around the world, having access to lower-cost generic medicines can mean the difference between health and sickness, solvency and bankruptcy for countless people.

Generic drugs hold great promise for the future. Growing acceptance of generics and favorable legislation in many geographies, combined with the large volume of branded products losing patent protection over the coming years is expanding the generic pharmaceuticals market.

Through our branded and unbranded Global Generics business, we fulfill our purpose of providing affordable medicines to more people around the world by offering lower-cost alternatives to highly-priced innovator brands both directly and through key partnerships.

Our capabilities span the entire value chain – from process development of the active pharmaceutical ingredient (API) to submission of the finished dosage dossier to the regulatory agencies – giving us control over the supply chain and the ability to offer high quality products at the right time and at competitive prices. Our state-of-the-art manufacturing facilities are ISO14001 and ISO9001 certified and have an excellent record of regulatory compliance. Our generics business is supported by our integrated Product Development Infrastructure which is dedicated to bringing new medicines to the market.

Today, we have a strong presence both in highly regulated markets like the US, UK and Germany and in emerging markets, including India, Russia, Venezuela, Romania, and CIS (Belarus, Ukraine and Kazakhstan). Moreover, we are steadily building our presence in other key markets.